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Introduction. The aim of this study was to differentiate between Candida famata and Candida guilliermondii correctly by using
matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) and gene sequencing. Methods.
Twenty-eight Candida strains from blood cultures that had been identified as C. famata (𝑁 = 25), C. famata/C. guilliermondii
(𝑁 = 2), and C. guilliermondii (𝑁 = 1) by the VITEK 2 system using the YST ID card were included. We identified these strains
by MALDI-TOFMS and gene sequencing using the 28S rRNA and ITS genes and compared the results with those obtained by the
VITEK2 system.Results. All 28 isolateswere finally identified asC. guilliermondii. Sequencing analysis of the 28S rRNAgene showed
99.80%–100% similarity with C. guilliermondii for all 28 strains. The ITS gene sequencing of the strains showed 98.34%–100%
homology with C. guilliermondii. ByMALDI-TOF, we could correctly identify 21 (75%) of 28 C. guilliermondii isolates. Conclusion.
We should suspect misidentification when C. famata is reported by the VITEK 2 system, and we always should keep in mind the
possibility of misidentification of any organism when an uncommon species is reported.
1. Introduction
Bloodstream infections caused by Candida species have
increased significantly over recent decades and are associated
with high rates of morbidity and mortality [1, 2]. A rapid
and accurate identification of Candida species is of great
importance to the selection of appropriate antifungal agents
and for appropriate patient management [3].
We have faced an increase in Candida famata isolation
from blood cultures with the use of the VITEK 2 system
in the clinical laboratory. This organism usually is found on
natural substrates and has been reported as a rare pathogen
of human beings [4–7].Candida famata andC. guilliermondii
are extremely difficult to differentiate by phenotypic features
[8, 9], so we need to determine whether the recent increase
of C. famata in the blood is true or reflects an error by the
identification system because of the organism’s similarity in
biochemical characteristics to other Candida spp.
The aim of this study was to identify these strains
correctly using matrix-assisted laser desorption/ionization-
time of flight mass spectrometry (MALDI-TOFMS) and 28S
rRNA and ITS gene sequencing.
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2. Materials and Methods
2.1. Strains. Twenty-eight nonduplicated Candida strains
identified as C. famata (𝑁 = 25), C. famata/C. guilliermondii
(𝑁 = 2), or Candida guilliermondii (𝑁 = 1) by the VITEK
2 system using the YST-ID card were included. All 28 strains
were collected from blood culture at Inje University Busan
Paik Hospital in the Republic of Korea between January 2007
and December 2008. We selected 25 nonduplicated strains
identified as C. famata (identification scores 92%–95%) and
2 nonduplicated strains showing a result of C. famata/C.
guilliermondii (50%/50%) by the VITEK system. We selected
these strains to achieve even distribution throughout the
isolation period and the admission ward. One Candida
guilliermondii isolate (97%) was used as a control. All isolates
were stored in skim milk at −80∘C until testing.
2.2. Phenotypic Characterization. Fungal culture and identi-
fication were performed by standard procedures in a clinical
microbiology laboratory. Yeast-form fungi were identified
according to conventional biochemical laboratory methods
by the VITEK 2 system using YST-ID. All procedures
were done according to the manufacturer’s instruction. We
repeated the identification procedures twice using the same
YST-ID for all strains.
2.3. MALDI-TOF MS Analysis. We identified all strains
with MALDI-TOFMS using MALDI Biotyper. MALDI-TOF
analyzes the unique protein spectra produced by extracts
of microbial cells. First, 𝛼-cyano-4-hydroxycinnamic acid
(HCCA portioned, number 255344, Bruker Daltonik GmbH,
Bremen, Germany) was prepared as the MALDI matrix
for Bruker MALDI Biotyper measurements. Colonies were
transferred to a steel target, namely, MSP 96 polished steel
(Bruker Daltonics), and overlaid with 1𝜇L of matrix solution
directly after drying. The extraction steps were done as
follows. Briefly, samples were prepared using formic acid and
acetonitrile after alcohol treatment, and then 1 𝜇L of extract
supernatant fluid was used for analysis. Spectra were auto-
matically concentrated on a maximum of 240 shots by MBT
autoX and then comparedwith the BrukerDaltonics database
using the MALDI Biotyper RTC software. We repeated test
with extraction method if no result was obtained.
2.4. Gene Sequencing. All Candida strains were identified by
polymerase chain reaction (PCR) and by direct sequencing
of the 28S rRNA and ITS genes. The fungal genomic DNA
collected from a single colony of an overnight culture was
extracted with InstaGene Matrix kit (Bio-Rad Laboratories,
Hercules, CA USA) according to the manufacturer’s recom-
mendation.
The ITS gene was amplified using the universal fungal
primers ITS1 (5󸀠-TCC GTA GGT GAA CCT GCG G-3󸀠)
and ITS4 (5󸀠-TCC TCC GCT TAT TGA TAT GC-3󸀠). The
28S rRNA gene was amplified with the primers D1/D2-F
(5󸀠-GCA TAT CAA TAA GCG GAG GAA AAG-3󸀠) and
D1/D2-R (5󸀠-GGT CCG TGT TTC AAG ACG G-3󸀠) as
previously described [10]. The primers for sequencing were
the same as those for PCR amplification. Both strands of
the purified DNA from the PCR were sequenced directly
with a Big Dye Terminator Cycle Sequencing kit (Applied
Biosystems, Foster City, CA) and the ABI PRISM 3130
genetic analyzer (Applied Biosystems). The sequences were
compared with those of the type and reference strains to con-
firm species identification using NCBI (a genome database
of the National Center for Biotechnology Information).
Phylogenetic analyses were performed for the 28S rRNA
and ITS using the neighbor-joining method with MEGA
version 4.
3. Results
All 28 isolates were finally identified as C. guilliermondii,
although 27 had been reported as C. famata (𝑁 = 25) or
C. famata/C. guilliermondii (𝑁 = 2) by the VITEK 2 system
using the YST-ID card. There was no true C. famata strain.
Thus, we could confirm that C. famata is a rare cause of
fungemia, its diagnosis being attributable to the misidenti-
fication of C. guilliermondii as C. famata by the VITEK 2
system.
The MALDI-TOF MS method was valuable for identifi-
cation of C. guilliermondii. We could correctly identify 21 C.
guilliermondii isolates that had been identified as C. famata
(𝑁 = 18), C. famata/C. guilliermondii (𝑁 = 2), or C.
guilliermondii (𝑁 = 1) by VITEK 2. Two strains showed
a score of more than 2.0 by the Bruker MALDI Biotyper,
whereas the scores of 19 strains were between 1.7 and 1.99.
The remaining seven isolates could not be identified to the
species level even though we retested and used the extraction
method. They showed scores of less than 1.7, and we defined
the result as no identification (Table 1).
The final correct identification could be acquired from
the use of 28S rRNA and ITS sequencing. We compared
the analyzed sequences from the clinical isolates with those
of type and reference strains obtained from the NCBI
database. By using 28S rRNA gene sequencing, all the 28
isolates were clearly identified as C. guilliermondii with a
similarity between 99.80% and 100%, and these strains also
showed close similarity to C. carpophila (99.65%–99.82%)
and C. caribbica (99.30%–99.47%). For ITS sequencing, all
28 isolates were first identified as C. guilliermondii, showing
similarity between 98.34% and 100%. However, the similarity
with C. caribbica was also very high (99.03%–99.23%). To
differentiate these closely related species, we constructed a
phylogenetic tree using the neighbor-joining method with
MEGA version 4. By this method, all strains were clustered
with C. guilliermondii, and these were obviously distin-
guished from C. famata by both genes. For the phylogenetic
tree of the 28S rRNA gene, C. guilliermondii strains were
clearly differentiated from C. caribbica, but not from C.
carpophila (Figure 1). When using the ITS sequence, all
isolates were clustered as one group with C. guilliermondii,
and this group was separated from C. caribbica and C.
carpophila (Figure 2).
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Table 1: VITEK 2 system, MALDI-TOF MS, and sequencing results for 28 Candida strains.
Strain VITEK 2 MALDI-TOF MS Sequencing
Identification Score Identification Score ID (28S gene) Similarity ID (ITS gene) Similarity
M07-1257 C. guilliermondii 97% C. guilliermondii 1.791 C. guilliermondii 100% C. guilliermondii 100%
M07-1410 C. famata 95% C. guilliermondii 1.782 C. guilliermondii 100% C. guilliermondii 99.81%
M07-1525 C. famata 95% C. guilliermondii 1.882 C. guilliermondii 100% C. guilliermondii 99.81%
M07-1575 C. famata 95% No ID∗ 1.682 C. guilliermondii 100% C. guilliermondii 99.81%
M07-1586 C. famata 95% C. guilliermondii 1.878 C. guilliermondii 100% C. guilliermondii 98.34%
M07-1601 C. famata 93% C. guilliermondii 1.951 C. guilliermondii 100% C. guilliermondii 99.81%
M07-1627 C. famata 95% C. guilliermondii 1.864 C. guilliermondii 100% C. guilliermondii 99.81%
M07-1639 C. famata 95% No ID∗ 1.700 C. guilliermondii 100% C. guilliermondii 99.81%
M08-0109 C. famata 95% C. guilliermondii 1.832 C. guilliermondii 100% C. guilliermondii 99.81%
M08-0121 C. famata 95% C. guilliermondii 1.951 C. guilliermondii 100% C. guilliermondii 99.81%
M08-0160 C. famata 95% C. guilliermondii 1.917 C. guilliermondii 100% C. guilliermondii 99.81%
M08-0197 C. famata 95% C. guilliermondii 1.719 C. guilliermondii 100% C. guilliermondii 99.63%
M08-0217 C. famata 95% C. guilliermondii 1.892 C. guilliermondii 100% C. guilliermondii 99.81%
M08-0227 C. famata 95% C. guilliermondii 1.726 C. guilliermondii 99.80% C. guilliermondii 99.81%
M08-0296 C. famata 95% C. guilliermondii 1.872 C. guilliermondii 100% C. guilliermondii 99.81%
M08-0328 C. famata/C. guilliermondii 50%/50% C. guilliermondii 2.068 C. guilliermondii 100% C. guilliermondii 99.81%
M08-1839 C. famata 92% No ID∗ 1.615 C. guilliermondii 100% C. guilliermondii 99.81%
M08-1847 C. famata 95% No ID∗ 1.492 C. guilliermondii 100% C. guilliermondii 99.81%
M08-1848 C. famata 95% C. guilliermondii 1.825 C. guilliermondii 99.80% C. guilliermondii 99.81%
M08-1849 C. famata 95% No ID∗ 1.394 C. guilliermondii 100% C. guilliermondii 99.81%
M08-1850 C. famata 95% C. guilliermondii 2.030 C. guilliermondii 100% C. guilliermondii 99.81%
M08-1851∗ C. famata/C. guilliermondii 50%/50% C. guilliermondii 1.992 C. guilliermondii 100% C. guilliermondii 99.81%
M08-1852 C. famata 95% No ID∗ 1.649 C. guilliermondii 100% C. guilliermondii 99.81%
M08-1854 C. famata 95% C. guilliermondii 1.883 C. guilliermondii 99.80% C. guilliermondii 99.81%
M08-1855 C. famata 95% No ID∗ 1.637 C. guilliermondii 99.80% C. guilliermondii 99.81%
M08-1857 C. famata 95% C. guilliermondii 1.854 C. guilliermondii 100% C. guilliermondii 99.81%
M08-1876 C. famata 95% C. guilliermondii 1.722 C. guilliermondii 100% C. guilliermondii 99.81%
M08-1898 C. famata 92% C. guilliermondii 1.939 C. guilliermondii 100% C. guilliermondii 99.81%
∗No ID: not reliable identification.
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Figure 1: Phylogenetic analysis using the neighbor-joiningmethod based on the 28S rDNA gene sequence for 28 clinical isolates and type and
reference strains.The scale bar represents the distance between strains.∗M07-1257 represents other strains that have 100% sequence similarity
to purported 21 C. famata, 1 C. guilliermondii, and 2 C. famata/C. guilliermondii strains.
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Figure 2: Phylogenetic analysis using the neighbor-joining method based on the ITS sequence for 28 clinical isolates and type and reference
strains.The scale bar represents the distance between strains. ∗M07-1410 represents strains that have 100% sequence similarity to the purported
21 C. famata, 1 C. guilliermondii, and 2 C. famata/C. guilliermondii strains.
4. Discussion
Candida species are the fourth most common cause of
nosocomial bloodstream infections [11]. Candida albicans is
still the most common species isolated from human beings;
however, the frequency of non-albicans Candida species is
increasing as a major cause of catheter-related bloodstream
infections especially [12].
Candida famata is a rare cause of invasive infection.
This strain was described as Torula candida after being
discovered in Japan [13]. It then was called Torulopsis famata
and Debaryomyces hansenii and finally defined as C. famata.
It occupies the human skin, vagina, and oral cavity as a
colonizing organism, so it has been considered a contaminant
even though it has been isolated from clinical specimens
[13, 14].
However, there are several reports concerning invasive
candidiasis caused by C. famata, and it should be considered
an important opportunistic pathogen. The most impor-
tant disease caused by C. famata is intravenous catheter-
associated candidemia in immunocompromised patients, as
described by St.-Germain and Laverdiere [7] in a bone mar-
row transplant patient. It also has been detected in patients
with endophthalmitis with chronic intraocular inflammation
[15], candidemia with aplastic anemia, and central catheter-
ization [13] and fatal peritonitis in a patient undergoing
continuous ambulatory peritoneal dialysis [16].
In clinical laboratories, most bacteria and yeasts are
routinely identified by biochemical characteristics using a
commercial kit or automated identification system such as
API and VITEK. Renneberg et al. [17] reported evaluation
by the Staph ID 32 and StaphZym systems for coagulase-
negative staphylococci showing a high rate of misidentifica-
tion. This phenomenon is obvious when some species have
high similarity in biochemical reactions. Misidentification
also is possible for Candida species when commercial kits
such as API 20C are used for identification [10]. Candida
famata is very similar in biochemical characteristics to C.
guilliermondii and C. caribbica. Desnos-Ollivier et al. [9]
reported that several C. famata strains identified by API
32C were C. guilliermondii, C. haemulonii, C. lusitaniae, and
C. palmioleophila when gene sequencing was done. More
recently, there was an interesting report of misidentification
of C. parapsilosis as C. famata in vertebral osteomyelitis [18].
The authors of that paper asserted the importance of this
problem because of differences in antifungal susceptibility
[3], especially the fact that the resistance rate to fluconazole
and amphotericin B is high in C. guilliermondii. Similar
misidentification can be seen in the identification of mold-
form fungi [19]. We agree with their recommendation con-
cerning the importance of using many molecular techniques
for diagnosis of infectious diseases to overcome the limits of
conventional methods [20, 21].
The VITEK 2 system is one of the most common auto-
mated identification systems using a colorimetric identifica-
tion card of YST. In previous reports, it was noted to be of
high sensitivity and specificity greater than 95% for common
Candida species isolated from clinical specimens compared
with molecular methods [22, 23]. On the other hand, the
identification rates for C. parapsilosis by the VITEK 2 system
were reported to be as low as 71.7%, although it can be
improved to 93.3% by examining the morphologic features
on cornmeal agar plates [23].
At first, we reported the results as C. famata for 25 strains
because the identification scores were high (identification
scores: 92%–95%) by the VITEK 2 system. However, the
isolation of C. famata by the VITEK 2 system has increased
in our clinical microbiology laboratory, and this is unusual
for us. So we assumed either the possibility of a change in the
distribution ofCandida species isolated fromblood culture or
some error in identification by the VITEK 2 system.We tried
to identify these isolates correctly usingMALDI-TOFMS and
28S rRNA and ITS gene sequencing analysis, and we finally
confirmed the misidentification by the VITEK 2 System of
C. guilliermondii as C. famata in clinical isolates from blood
culture.
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Many microbes show similar patterns of biochemical
reactions, and we have difficulty in identification. Broad-
range PCR and gene sequencing is a good tool for the
correct identification of fungi, and 28S rRNA and ITS are well
known as useful regions for identification of fungi [24]. This
technique allows more accurate identification of Candida
species based on differences in the rRNA [25, 26]. In this
study, all isolates were identified as C. guilliermondii using
the 28S rRNA and ITS genes. We found that the 28S rRNA
gene could not discriminate between C. guilliermondii and C.
carpophila because of the high similarity of their sequences.
However, these regions could distinguish between C. famata
and C. guilliermondii.
In recent years, MALDI-TOF MS was introduced as a
technique for molecular identification [27]. This technique
has a profound advantage of rapid identification to the
species level within a few minutes. We evaluated its ability
to correctly identify C. guilliermondii. We analyzed these 28
Candida strains according to the recommendations of the
manufacturers. Among the 28 Candida species, two isolates
showed a score of more than 2.0 and were C. guilliermondii.
Nineteen isolates gave a result of C. guilliermondii, but the
scores were between 1.7 and 2.0.We got nonreliable results for
7 strains even though we retested after extraction. Stevenson
et al. [28] evaluated the clinical usefulness of MALDI-TOF
MS for the identification of yeasts by their own library using
109 reference and type strains. They could identify isolates
correctly to the species level in 192 (97.5%) of 197 isolates
with 100% correct identification of all 15 C. guilliermondii.
Lacroix et al. [29] compared two MALDI-TOF MS systems,
Andromas and Bruker MaldiBiotyper, with conventional
identification methods using 1383 clinical Candida isolates.
The correct identification rates of the two MALDI-TOF MS
systems (98.2%) were higher than those of conventional
methods (96.5%) by comparison with sequencing results.
Bruker MaldiBiotyper recommends that a score greater than
2.0 be identified to the species level and to the genus level if
the values are greater than 1.70 but lower than 2.0. It gives
“Not reliable identification” if the values are lower than 1.70.
However, only 2 strains were higher than 2.0 in this study,
so we would recommend a cutoff value of 1.7 to identify C.
guilliermondii.
In conclusion, we confirmed the misidentification of C.
guilliermondii as C. famata by the VITEK 2 YST system. We
now suspect misidentification when C. famata is reported
by the VITEK 2 system, and we always keep in mind the
possibility of misidentification when an uncommon species
is reported.
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